Nikko Asset Management Americas Inc. Sells 2,730 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nikko Asset Management Americas Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,154 shares of the biopharmaceutical company’s stock after selling 2,730 shares during the period. Nikko Asset Management Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $18,630,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $28,000. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on REGN. Wells Fargo & Company dropped their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Citigroup decreased their price target on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $666.87 on Monday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The firm has a market capitalization of $72.91 billion, a PE ratio of 17.42, a P/E/G ratio of 2.34 and a beta of 0.27. The firm has a 50-day moving average of $694.91 and a two-hundred day moving average of $831.18.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the company posted $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. On average, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. Regeneron Pharmaceuticals’s dividend payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.